Citius Oncology, Inc.

Executive Summary

Citius Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for hematologic cancers. Its lead candidate, LYMPHIR (denileukin diftitox), is an IL-2-based immunotherapy approved for the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL). In May 2026, the company secured up to $36.5 million in debt and equity financing to accelerate the commercialization of LYMPHIR, signaling a transition from development to a commercial-stage entity. The company operates in Cranford, New Jersey, and was founded in 2020 as a spin-off from Citius Pharmaceuticals. With a validated product and a clear path to market, Citius Oncology is positioned to address an unmet need in CTCL and potentially expand into other hematologic malignancies. The recent capital raise removes a key near-term financing risk and provides resources for sales force expansion, market access, and physician education.

Upcoming Catalysts (preview)

• Q3 2026Full Commercial Launch of LYMPHIR for CTCL90% success
• 2027Potential FDA Approval for Expanded Indication (e.g., PTCL or other lymphomas)40% success
• 2026Strategic Partnership or License Agreement for ex-U.S. Rights60% success